Sabra Health Care REIT, Inc. (SBRA) 股票分析

公司概述

Sabra Health Care REIT, Inc. operates as a self-administered and self-managed real estate investment trust that owns and invests in real estate assets specifically serving the healthcare industry across the United States and Canada. The company functions within the Real Estate sector and the REIT - Healthcare Facilities industry, a classification that indicates its primary exposure to properties leased to healthcare providers rather than traditional residential or commercial tenants. This entity maintains a substantial scale with a market capitalization of $5.06B and generates annual revenue of $775.76M while employing 58 individuals to manage its extensive portfolio. The combination of a $5.06B market cap and nearly $776M in revenue suggests that Sabra holds a significant position within the specialized healthcare real estate niche, reflecting investor confidence in the demand for medical facilities despite the high operational leverage typical of the REIT structure.

财务健康

The company reported revenue of $775.76M over the trailing twelve months, with net income of $155.61M and EBITDA reaching $447.11M, highlighting a significant gap between operating earnings and net income that reveals a substantial cost structure dominated by interest expenses and taxes. This disparity underscores the heavy financial burden of debt servicing, which is further evidenced by the company holding $74.92M in cash against a total debt load of $2.54B. The balance sheet is clearly leveraged rather than conservative, as indicated by a debt-to-equity ratio of 89.86, meaning the company relies heavily on borrowed capital to finance its assets. Short-term liquidity appears robust with a current ratio of 1.80, indicating that current assets are more than double current liabilities, though this must be weighed against the massive absolute debt figure. Return on Equity stands at 5.6% while Return on Assets is 3.1%, metrics that reveal management's effectiveness in generating profit from shareholder equity is moderate but constrained by the high level of financial leverage inherent in the business model.

估值评估

Valuation multiples for Sabra Health Care REIT, Inc. show a trailing P/E ratio of 31.38 compared to a forward P/E of 25.58, implying that the market expects earnings to increase significantly in the coming year to justify the current price. The price-to-book ratio is 1.79, indicating that the stock trades at a 79% premium over its book value, which often reflects the intangible value of long-term leases and the stability of the healthcare tenant base. Alternative valuation metrics such as the price-to-sales ratio of 6.53 and an EV/EBITDA of 16.84 suggest the market prices the company based on revenue generation and enterprise value efficiency rather than just current earnings. The stock's 52-week trading range spans from a low of $15.75 to a high of $21.07, providing context for recent price volatility within a relatively narrow band. The beta value of 0.65 indicates that the stock exhibits lower price volatility relative to the broader market, suggesting it may act as a defensive holding within a diversified portfolio.

Growth & Income

Growth dynamics present a mixed profile with revenue growth of 15.8% year-over-year contrasted sharply by earnings growth of -44.7% year-over-year, implying that earnings are growing significantly slower than revenue, likely due to one-time costs or increased interest expenses eroding profitability. As a dividend payer, the company offers a dividend yield of 6.0% with a payout ratio of 187.5%, a metric that suggests the dividend is not sustainable given current earnings levels and may require capital recycling or asset sales to maintain. The high payout ratio relative to net income indicates that the company is distributing more cash than its reported earnings, which could signal a reliance on cash flow from operations rather than accounting profit for dividend funding. Overall, the company presents a high-yield income profile coupled with modest revenue expansion but faces challenges in translating that revenue growth into proportional earnings growth under current cost structures.